Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536495 | 1.00 | PRKDC (0.61) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058525 | 0.87 | PRKDC (0.75) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7275734 | 0.87 | PRKDC (0.60) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL552259 | 0.86 | PRKDC (0.60) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15801109 | 0.86 | PRKDC (0.78) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31536496 | 0.85 | IP6K1 (0.63) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1317583 | 0.83 | IP6K1 (0.66) | PKMMAPTIP6K1KDM4EMEN1 | |
| SCHEMBL939936 | 0.83 | IP6K1 (0.74) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058325 | 0.82 | PRKDC (0.59) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31536499 | 0.81 | PKM (0.55) | PKMMAPTIP6K1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | NORTH CAROLINA CENTRAL UNIV (US) | 2018-12-27 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | PRKDC 4156/4885PIK3CD 3144/4885PIK3CA 1972/4885 |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | GLS2, PC, GLS | PRKDC 4156/4885PIK3CD 3144/4885PIK3CA 1972/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | PRKDC 4156/4885PIK3CD 3144/4885PIK3CA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.